Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue Samples

August 27th 2024

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Dr Dreicer on the Complexities of Prostate Cancer

August 23rd 2024

Robert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Dr Morgans on Considerations for Treating nmCRPC in the Community Setting

August 22nd 2024

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Dr Ravi on the Investigation of RCB Following ARPI Treatment in High-Risk Prostate Cancer

August 21st 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

August 20th 2024

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC

August 16th 2024

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPC

August 16th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.

Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer

August 14th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

August 9th 2024

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer

August 6th 2024

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPC

July 31st 2024

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Dreicer on Managing Biochemical Failure Post-Radical Prostatectomy in Prostate Cancer

July 31st 2024

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer

July 29th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

July 25th 2024

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

July 24th 2024

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPC

July 23rd 2024

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19th 2024

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Final Thoughts on CSPC

July 17th 2024

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.